LOXO-BTK-1800 is now open

LOXO-BTK-1800 is now open

A new Clinical Trial is now open at LINEAR Research Institute:

LOXO-BTK-1800

This study is for patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Non-Hodgkin lymphoma (NHL) who have failed or are intolerant to standard of care treatment.

The study includes two parts:
Phase 1 is a dose escalation, where the maximum tolerated dose of LOXO-305 will be evaluated
Phase 2 is a dose expansion, where patients will receive the established recommended dose of LOXO-305

For further information and contact details, please see our Open to Recruitment page:
www.bloodcancerwa.org.au/trial/loxo-btk-1800/

Share this post